US Patent 9,669,019: Scope, Claims, Expiration, Orange Book Status, and Apomorphine Patent Landscape
US Patent No. 9,669,019 protects a sublingual, mucoadhesive apomorphine film containing an acid-addition salt, principally apomorphine hydrochloride, and a pH-neutralizing agent. The patent also covers specified excipients, dose ranges, layered film architecture, rapid plasma exposure, Parkinson's disease treatment, and relief of "off" episodes.
The patent issued June 6, 2017, and is associated with the KYNMOBI apomorphine sublingual film product. Its ordinary US patent-term expiration is June 25, 2031, subject to the term shown in the FDA Orange Book and any applicable patent-term adjustment or disclaimer.[1,2]
What does US Patent 9,669,019 protect?
The independent composition claim requires a combination of structural, chemical, manufacturing, and dosage-form elements. A potentially infringing product must satisfy all limitations of claim 1 or an applicable dependent claim.
| Claim element |
Required scope |
| Administration route |
Sublingual administration |
| Dosage form |
Unit-dose mucoadhesive film |
| Active ingredient |
Apomorphine particles containing an acid-addition salt |
| Principal salt |
Apomorphine hydrochloride is expressly claimed in claim 4 |
| Neutralizing component |
A pH-neutralizing agent |
| Film process |
Mixing polymer, apomorphine salt particles, and solvent |
| Film formation |
Pouring the mixture onto a surface and evaporating solvent |
| Neutralizer incorporation |
Contacting or impregnating the first film or mixture with the pH-neutralizing agent |
| Therapeutic use |
Treatment of Parkinson's disease under claim 19 |
| Clinical result |
At least 3 ng/mL average circulating apomorphine concentration within 20 minutes under claim 25 |
The claim is narrower than a general claim to any apomorphine oral film. It requires the combination of apomorphine salt particles and pH neutralization in a mucoadhesive sublingual film made through the recited solvent-casting process.
How broad is claim 1 of US 9,669,019?
Claim 1 has meaningful breadth because it does not limit the invention to one polymer, one neutralizer, one antioxidant, one plasticizer, or one dose. It covers a functional class of pH-neutralizing agents and a broad set of film-forming manufacturing conditions.
Its principal limitations are also substantial:
- The product must be a mucoadhesive film.
- The film must be formulated for sublingual administration.
- Apomorphine must be present as particles containing an acid-addition salt.
- A pH-neutralizing agent must be incorporated into the film or used to contact the first film.
- The manufacturing sequence must include mixture formation, casting or pouring, and solvent evaporation.
A competing product could avoid literal infringement by using a non-film dosage form, a buccal or subcutaneous route, a non-salt form of apomorphine, a fully dissolved apomorphine formulation without claimed particles, or a manufacturing process that does not practice the recited casting and neutralizer-contacting steps. The doctrine of equivalents could still be relevant, but its application would depend on claim construction and the prosecution history.
Which dependent claims add the most commercial protection?
Claims 2 through 18 narrow the composition by adding excipients or dose ranges. Claims 22 through 31 add layered architecture, non-effervescent behavior, pharmacokinetics, and selected formulation components.
Neutralizing agents
Claims 2 and 3 focus on inorganic bases, including:
- Sodium phosphate monobasic
- Sodium phosphate dibasic
- Sodium phosphate tribasic
- Potassium phosphate monobasic
- Potassium phosphate dibasic
- Potassium phosphate tribasic
- Mixtures of those salts
Claim 21 covers organic bases, although its reference to "the method of claim 1" appears to be a drafting or dependency error because claim 1 is a composition claim. The operative scope should be evaluated against the issued claim text, prosecution history, and applicable claim-construction principles.
Antioxidants and chelators
Claims 5 through 9 cover antioxidant-containing films. Claim 7 specifically identifies sodium metabisulfite, while claims 8 and 9 cover metal chelators and EDTA.
These limitations are commercially relevant because apomorphine is susceptible to oxidative degradation. A generic or follow-on manufacturer that uses sodium metabisulfite or EDTA in an otherwise matching formulation could fall within the dependent claims even if it disputes claim 1.
Plasticizers
Claims 10 and 11 cover plasticizers, including glycerol. The broader list includes propylene glycol, fatty-acid esters, sorbitan esters, citric-acid esters, PEG 400, triacetin, mannitol, xylitol, and sorbitol.
Plasticizer claims can create a second layer of infringement risk because film products commonly require a plasticizer to improve flexibility, handling, and dissolution.
Dose ranges
The patent covers films containing 2 to 40 mg of apomorphine acid-addition salt under claim 12. Narrower ranges include:
| Claim |
Dose limitation |
| 13 |
10 ± 3 mg |
| 14 |
15 ± 3 mg |
| 15 |
22 ± 4 mg |
| 16 |
27 ± 4 mg |
| 17 |
30 ± 5 mg |
| 18 |
35 ± 5 mg |
| 28 |
12 to 30 mg |
Claims 29 through 31 expressly apply the 12-to-30 mg range to apomorphine hydrochloride.
These claims may cover multiple commercial strengths and make a simple dose-switch strategy less effective. A product using a dose outside the claimed ranges could still infringe claim 1 if the remaining limitations are met.
What formulations are protected by US 9,669,019?
The patent protects several formulation configurations rather than one fixed recipe.
Single-phase mucoadhesive film
The broadest configuration is a film containing apomorphine salt particles, film-forming polymer, solvent-derived film structure, and a pH-neutralizing agent.
Two-portion or bilayer film
Claim 22 covers a first portion containing the apomorphine particles and a second portion containing the pH-neutralizing agent. Claim 23 specifies that the portions can be separate layers.
This architecture is important because it does not require the neutralizer to be uniformly dispersed throughout the original casting mixture. The patent reaches films produced by contacting the first film with the neutralizing-agent portion.
Non-effervescent film
Claim 24 covers a non-effervescent mucoadhesive film. This limitation distinguishes the claimed system from effervescent oral films that generate gas through acid-base reactions.
Pharmacokinetic performance
Claim 25 requires an average circulating apomorphine plasma concentration of at least 3 ng/mL within 20 minutes after sublingual administration. This is a product-performance limitation. Enforcement may require analytical testing, clinical evidence, or validated pharmacokinetic data.
Permeation enhancer and glycerol monostearate
Claims 26 and 27 add a permeation enhancer and glycerol monostearate, respectively. These claims may capture formulations designed to increase mucosal transport or modify film performance.
When does US Patent 9,669,019 expire?
The patent is generally identified with a June 25, 2031 expiration date.[1,2] The relevant timeline is:
| Event |
Date |
| Earliest priority date |
June 25, 2010 |
| US patent issuance |
June 6, 2017 |
| Ordinary 20-year term endpoint |
June 25, 2031 |
| FDA-listed product association |
KYNMOBI, apomorphine hydrochloride sublingual film |
| Earliest ordinary generic-entry point |
After expiration, unless earlier entry results from litigation, settlement, license, or non-infringing design |
The effective expiration date should be taken from the current USPTO and Orange Book records rather than calculated solely from the issue date. Patent term is normally measured from the earliest effective nonprovisional filing date, not from issuance.[2,3]
What is the Orange Book status of US 9,669,019?
US Patent 9,669,019 is associated with KYNMOBI, the FDA-approved apomorphine hydrochloride sublingual film marketed for intermittent treatment of "off" episodes in patients with Parkinson's disease.[1,4]
The Orange Book analysis should distinguish between:
- Patent listing for the approved drug product
- Patent expiration
- FDA marketing exclusivity
- Pediatric exclusivity
- Any use code attached to the listing
- Current listing status and delisting activity
The patent itself does not create FDA exclusivity independent of its patent rights. A generic applicant may challenge an Orange Book-listed patent through a Paragraph IV certification, seek approval with a Paragraph III certification, or file a section viii statement where the patent claims only a use that the applicant omits from its labeling.[5]
What FDA exclusivity protects KYNMOBI?
KYNMOBI received FDA approval in May 2020 under NDA 210625.[4] The principal regulatory protection is distinct from US Patent 9,669,019.
| Protection |
General effect |
| New chemical entity exclusivity |
Blocks certain abbreviated applications for five years from approval, subject to Paragraph IV rules |
| Patent protection |
Can block approval or support litigation through the patent term |
| Listed method-of-use patents |
May require a Paragraph IV challenge or section viii carve-out |
| Orphan-drug exclusivity |
Does not appear to be the principal KYNMOBI exclusivity mechanism |
| Pediatric exclusivity |
Applies only if separately granted and listed |
The FDA approval date and patent term should not be treated as interchangeable. Regulatory exclusivity may expire before the patent, while a patent may remain enforceable after generic filing becomes legally available.
What Paragraph IV risks exist for a generic KYNMOBI?
A generic applicant seeking an apomorphine sublingual film would face product-by-process and formulation risks.
Paragraph IV exposure
A Paragraph IV certification could challenge US 9,669,019 on grounds including:
- Lack of novelty
- Obviousness
- Lack of written description
- Lack of enablement
- Indefiniteness
- Non-infringement based on a different formulation or process
- Failure of the listed patent to claim the proposed product
Because claim 1 includes both product and manufacturing-process language, an ANDA applicant would need to analyze whether its commercial manufacturing process practices the claimed sequence. The applicant would also need to assess whether the product satisfies the particle, neutralizer, mucoadhesion, and sublingual limitations.
Potential 30-month stay
If the NDA holder or patent owner receives a valid Paragraph IV notice and files suit within the statutory period, FDA approval can be stayed for up to 30 months under the Hatch-Waxman framework, subject to statutory exceptions and court action.[5]
Design-around options
Potential design-around approaches include:
- A non-mucoadhesive sublingual tablet
- A spray, liquid, or rapidly dissolving solid
- A buccal rather than sublingual product
- A free-base or different apomorphine form
- A film made without acid-addition-salt particles
- A process that avoids the claimed neutralizer-contacting step
- A dose outside the narrower dependent claims
These approaches would not automatically avoid claim 1. The broad independent claim remains the central risk.
Which companies are challenging US 9,669,019?
Public patent-risk analysis requires separating a formal Paragraph IV filing from ordinary competitive development. An ANDA filing, Paragraph IV notice, district-court complaint, settlement, or license should not be inferred from the existence of a competing apomorphine product.
No specific Paragraph IV challenger, final judgment of invalidity, or published settlement should be treated as established solely from the patent claims supplied here. The relevant records are FDA Orange Book updates, USPTO Patent Center filings, district-court dockets, and Abbreviated New Drug Application litigation notices.
How strong is the patent estate for KYNMOBI?
US 9,669,019 is commercially important but should be analyzed as one member of a broader estate.
| Strength factor |
Assessment |
| Product coverage |
Strong for the claimed sublingual mucoadhesive film architecture |
| Active-ingredient coverage |
Limited to apomorphine acid-addition salts, with apomorphine hydrochloride specifically claimed |
| Process coverage |
Significant because casting, solvent evaporation, and neutralizer incorporation are recited |
| Dose coverage |
Broad 2-to-40 mg range plus multiple narrower ranges |
| Performance coverage |
Claim 25 adds rapid plasma-exposure protection |
| Excipient coverage |
Meaningful coverage for antioxidants, chelators, plasticizers, permeation enhancers, and glycerol monostearate |
| Design-around vulnerability |
Moderate, particularly through non-film dosage forms or different salt and manufacturing choices |
| Generic substitution risk |
High if an ANDA product copies the film, neutralizer, salt, and casting process |
| Biosimilar risk |
Not applicable |
Biosimilar law is not relevant because apomorphine hydrochloride is a small-molecule active pharmaceutical ingredient. Any follow-on product would generally proceed through the generic-drug framework, most likely an ANDA, rather than the biosimilar pathway under the Public Health Service Act.
What patent litigation affects the apomorphine sublingual market?
The principal litigation risk is Hatch-Waxman litigation involving an ANDA for a product referencing KYNMOBI. The key questions would be whether the proposed generic:
- Uses apomorphine hydrochloride or another acid-addition salt.
- Uses a mucoadhesive sublingual film.
- Contains a claimed neutralizer.
- Uses the claimed casting and solvent-evaporation sequence.
- Meets the claimed pharmacokinetic threshold.
- Includes a patented Parkinson's disease use in its proposed labeling.
A court could find non-infringement even where the generic is therapeutically substitutable. Conversely, a formulation that differs in inactive ingredients may still infringe if it satisfies all limitations of claim 1.
What licensing and commercial rights are relevant?
Cynapsus Therapeutics developed the apomorphine sublingual film platform and was acquired by Sunovion Pharmaceuticals in 2016. Sunovion commercialized KYNMOBI in the United States.[6] The commercial rights therefore reflect an acquisition and integration transaction rather than a simple arm's-length license publicly associated with US 9,669,019.
Sunovion Pharmaceuticals is part of Sumitomo Pharma. The ownership chain is relevant when assessing patent enforcement authority, Orange Book listing responsibility, settlement rights, and potential licensing of follow-on products.
How does US 9,669,019 compare with competing apomorphine products?
| Product |
Active ingredient |
Route |
Dosage form |
Main competitive position |
| KYNMOBI |
Apomorphine hydrochloride |
Sublingual |
Mucoadhesive film |
Rapid, non-injectable rescue treatment |
| APOKYN |
Apomorphine hydrochloride |
Subcutaneous |
Injection |
Established rescue therapy with injection burden |
| Other follow-on products |
Apomorphine or derivative |
Route-dependent |
May include infusion, injection, film, or oral systems |
Potentially outside the literal scope of US 9,669,019 |
US 9,669,019 is most relevant to products that copy KYNMOBI's sublingual film technology. It presents less direct risk to injectable or infusion products that do not use the claimed dosage form and manufacturing architecture.
Key Takeaways
- US 9,669,019 covers a sublingual mucoadhesive film containing apomorphine acid-addition-salt particles and a pH-neutralizing agent.
- Apomorphine hydrochloride is expressly claimed.
- The patent combines formulation, manufacturing-process, dose, excipient, layered-film, therapeutic-use, and pharmacokinetic limitations.
- The principal patent expiration date is June 25, 2031.
- The patent is associated with KYNMOBI, FDA-approved apomorphine hydrochloride sublingual film.
- A generic KYNMOBI film would face substantial Paragraph IV and infringement risk if it copies the claimed salt, neutralizer, film architecture, and solvent-casting process.
- The strongest design-around routes are non-film dosage forms, different administration routes, different apomorphine forms, and materially different manufacturing processes.
- Biosimilar risk does not apply because apomorphine is a small molecule.
- Patent term, Orange Book status, FDA exclusivity, litigation, and settlement rights must be analyzed separately.
FAQs
Is US 9,669,019 a formulation patent or a method-of-use patent?
It is principally a formulation and manufacturing patent, with additional method-of-treatment claims for Parkinson's disease and relief of "off" symptoms.
Does the patent cover every apomorphine sublingual product?
No. The claims require a mucoadhesive film, an acid-addition salt in particle form, a pH-neutralizing agent, and the claimed film-forming process or equivalent claim limitations.
Can a generic use a different apomorphine salt?
A different salt may reduce literal infringement risk under claims expressly directed to apomorphine hydrochloride, but claim 1 covers acid-addition salts more broadly. The full claim set and equivalents analysis would remain relevant.
Does FDA approval of KYNMOBI extend the patent term?
No. FDA approval and patent term are separate legal regimes. Approval may support Orange Book listing and Hatch-Waxman enforcement, but it does not itself extend the patent except through a statutory patent-term extension or adjustment reflected in official records.
Are injectable apomorphine products blocked by US 9,669,019?
Generally, the patent is directed to a sublingual mucoadhesive film. Injectable products ordinarily lack the claimed dosage form and route, although separate patents may affect injectable apomorphine products.
References
- U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,669,019, Sublingual apomorphine formulations.
- U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources. https://www.uspto.gov
- U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov
- U.S. Food and Drug Administration. (2020). KYNMOBI prescribing information. Sunovion Pharmaceuticals Inc.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob
- Sumitomo Pharma Co., Ltd. (2016). Cynapsus Therapeutics acquisition and apomorphine sublingual film commercialization materials.
